Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits
| Autor: | Maria Teresa Petrucci, Marta Chisini, Fabiana Gentilini, Paola Finsinger |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Medicine (miscellaneous) Review Pharmacology Quality of life Internal medicine hemic and lymphatic diseases medicine Pharmacology Toxicology and Pharmaceutics (miscellaneous) Multiple myeloma Lenalidomide intravenous bortezomib Bortezomib business.industry Health Policy medicine.disease Thalidomide Tolerability quality of life Novel agents Toxicity business Social Sciences (miscellaneous) patient preference medicine.drug |
| Zdroj: | Patient preference and adherence |
| ISSN: | 1177-889X |
| Popis: | The use of novel agents such as thalidomide, lenalidomide, and bortezomib has considerably improved the outcome of multiple myeloma patients. Besides greater biological activity, these drugs unfortunately have also been associated with greater toxicity. To evaluate the positive effect on the quality of life of patients, driven by both the tolerability and antimyeloma activity of bortezomib, we analyzed data that have been published concerning different strategies used to improve its tolerability as once weekly and/or subcutaneous administration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|